The Council for Scientific and Industrial Research (CSIR) launched the countrys first anti-diabetic ayurvedic drug for type two Diabetes mellitus. The drug BGR-34 is developed jointly by National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP), the Lucknow-based research units of CSIR.
The scientists of NBRI and CIMAP joined hands to develop an effective, safe, patient-friendly solution towards management of type two Diabetes. While the modern diabetes drugs are known for side-effects and toxicity, BGR-34 works by controlling blood sugar and limiting the harmful effects of other drugs.
BGR-34 is a unique product that manages the lives of people suffering from diabetes. One of the critical ingredients is that it inhibits DPP-4 and enhances insulin secretion. The product has passed several battery of tests and showed hypoglycemic activity in experimental subjects.
For the purpose of quality commercial production and extended distribution, AIMIL Pharmaceuticals (I) Ltds, known for its innovative Ayurvedic products, has been transferred the rights and technical knowhow to produce and market it for medical use.
K K Sharma, Managing Director of AIMIL pharmaceuticals, said, "We have decided to launch this marvelous anti-diabetic product in the name of BGR-34, which stands for Blood Glucost Regulator, containing 34 identified active phyto-constitutes from herbal resources."